University of California Berkeley
seal E. O. Lawrence Berkeley National
Laboratory seal
The
Carcinogenic Potency Project

Vinyl chloride (CAS 75-01-4)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ezy kid liv lun nas nrv ski tes vsc ezy kid liv mgl nas nrv vsc lun vsc lun mgl vsc 6.11m,v 21.8m

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
ezy sto vsc mgl ski sto vsc 39.4m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   ezy = ear/Zymbal’s gland. kid = kidney. liv = liver. lun = lung. mgl = mammary gland. nas = nasal cavity (includes tissues of the nose, nasal turbinates, paranasal sinuses and trachea). nrv = nervous system. ski = skin. sto = stomach. tes = testes. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Vinyl chloride: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

VINYL CHLORIDE 75-01-4 6490 H f syg inh 6m24 1536m 0 18.3mg Drew;txap,68,120-130;1983/Haseman pers.comm. mgl car es 32.3mg P<.0005 + 20.5mg 55.1mg 0/143 28/87 sto ade es 47.2mg P<.0005 + 27.1mg 105.mg 5/138 23/88 --- hes es 78.6mg P<.0005 + 41.4mg 177.mg 0/143 13/88 6491 H f syg inh 12m24 1536n 0 36.7mg mgl car es 27.7mg P<.0005 + 17.7mg 46.4mg 0/143 31/52 ski car es 121.mg P<.0005 + 56.9mg 330.mg 0/133 9/48 --- hes es 314.mg P<.002 + 108.mg 1.73gm 0/143 4/52 sto ade es 1.01gm P<.5 + 146.mg n.s.s. 5/138 3/50 6492 H f syg inh 18m24 1536o 0 55.0mg mgl car es 61.0mg P<.0005 + 42.5mg 91.6mg 0/143 47/102 sto ade es 205.mg P<.0005 + 110.mg 579.mg 5/138 20/101 --- hes es 1.92gm P<.07 + 473.mg n.s.s. 0/143 2/103 6493 H m syg inh 7m23 1BT8 0 3.18mg 20.9mg 34.6mg 181.mg 454.mg 756.mg Maltoni;aric,2,1-533;1984/ 1977a/1981 for epo ejz 55.0mg Z P<.0005 + 31.6mg 110.mg 3/47 3/22 4/18 9/23 17/19 (10/21 10/19) liv agm ejz 2.38gm * P<.01 + 821.mg 151.gm 0/38 0/13 0/10 0/15 2/13 1/9 1/11 adu epo ejz 855.mg Z P<.04 + 268.mg n.s.s. 0/27 0/13 0/9 3/13 1/13 2/8 (1/10) liv hpt ejz 1.73gm * P<.07 280.mg n.s.s. 0/15 0/4 0/3 0/5 0/3 1/3 0/1 ski mel ejz 7.63gm * P<.2 1.90gm n.s.s. 0/52 1/25 1/21 0/26 1/20 2/24 1/23 ski epo ejz 9.35gm Z P<.6 1.37gm n.s.s. 3/52 9/25 3/21 7/26 3/20 1/24 7/23 ehp agm ejz 9.80gm * P<.2 2.00gm n.s.s. 0/47 0/22 1/18 1/23 0/19 0/21 2/19 --- leu ejz 25.8gm * P<.9 1.55gm n.s.s. 8/60 6/30 6/30 5/30 9/30 6/30 5/30 liv ang ejz 91.8gm * P<1. 2.15gm n.s.s. 0/40 0/19 0/15 2/17 0/15 1/16 0/15 tba mix ejz no dre P=1. 992.mg n.s.s. 32/60 18/30 15/30 21/30 22/30 15/30 16/30 6494 M f cd1 inh 26w58 1113m 0 17.9mg 115.mg 459.mg Hong;jtxe,7,909-924;1981/1980 liv hes ejs 91.9mg * P<.0005 + 41.6mg 298.mg 1/28 1/8 2/8 8/12 lun abt ejs 142.mg * P<.03 50.6mg n.s.s. 7/28 1/8 4/8 7/12 mgl mal ejs 249.mg * P<.2 70.4mg n.s.s. 3/28 2/8 5/8 4/12 6495 M m cd1 inh 26w78 1113m 0 11.2mg 60.9mg 244.mg liv hes ejs 32.0mg Z P<.0005 + 13.4mg 104.mg 0/28 0/8 7/12 (5/12) lun abt ejs 88.7mg * P<.004 37.3mg 927.mg 4/28 2/8 8/12 7/12 6496 M f swi inh 30w77 1BT4 0 10.4mg 70.5mg 141.mg 758.mg 2.14gm 3.57gm Maltoni;aric,2,1-533;1984/ 1977a/1981 liv ang ejz 98.8mg Z P<.0005 + 55.8mg 199.mg 0/62 0/26 9/21 8/26 (10/24 11/21 9/20) liv agm ejz 196.mg Z P<.0005 + 95.6mg 687.mg 0/62 1/27 5/21 4/28 (3/26 5/24 5/25) lun ade ejz 402.mg Z P<.0005 + 248.mg 709.mg 7/67 3/30 17/29 26/29 22/30 24/29 26/28 ehp ang ejz 736.mg Z P<.003 + 318.mg 5.59gm 1/59 0/20 1/16 5/24 4/18 (1/14 1/12) mgl car ejz 3.75gm Z P<.005 + 1.69gm 41.6gm 1/67 11/30 12/29 7/28 8/30 8/28 13/28 for epo ejz 9.82gm * P<.02 2.41gm n.s.s. 0/56 0/18 0/13 0/20 1/13 0/9 1/6 liv hpt ejz 12.2gm Z P<.1 2.59gm n.s.s. 0/62 0/26 2/21 0/26 0/24 2/21 (0/20) ski epo ejz 25.1gm * P<.3 5.81gm n.s.s. 1/64 0/27 1/24 0/28 1/28 3/24 0/25 ehp agm ejz 70.9gm * P<.7 7.02gm n.s.s. 0/65 4/27 1/24 2/28 1/28 1/24 2/27 tba mix ejz 600.mg Z P<.0005 336.mg 1.34gm 22/70 16/30 22/30 28/30 23/30 25/30 28/30 6497 M f swi inh 6m24 1536m 0 10.1mg Drew;txap,68,120-130;1983/Haseman pers.comm. mgl car es 10.6mg P<.0005 + 6.81mg 18.3mg 2/71 33/67 --- hes es 12.5mg P<.0005 + 7.87mg 21.9mg 1/71 29/67 lun car es 36.6mg P<.03 + 15.4mg n.s.s. 9/71 18/65 6498 M f swi inh 12m24 1536n 0 20.2mg --- hes es 13.8mg P<.0005 + 8.64mg 23.7mg 1/71 30/47 mgl car es 22.9mg P<.0005 + 13.4mg 45.2mg 2/71 22/47 lun car es 55.5mg P<.02 + 23.7mg n.s.s. 9/71 15/47 6499 M f swi inh 18m24 1536o 0 30.2mg mgl car es 32.2mg P<.0005 + 18.9mg 63.3mg 2/71 22/45 --- hes es 36.1mg P<.0005 + 20.9mg 71.4mg 1/71 20/45 lun car es 143.mg P<.2 + 47.0mg n.s.s. 9/71 11/45 6500 M m swi inh 30w77 1BT4 0 11.0mg 43.5mg 149.mg 587.mg 1.96gm 3.62gm Maltoni;aric,2,1-533;1984/ 1977a/1981 lun ade ejz 14.0mg Z P<.0005 + 8.17mg 27.3mg 8/75 3/27 24/29 (24/29 18/25 23/27 20/24) liv ang ejz 70.8mg Z P<.0005 + 39.2mg 149.mg 0/62 1/18 9/23 6/17 (6/13 2/12 1/9) ski epo ejz 2.69gm * P<.0005 1.30gm 8.63gm 1/66 0/20 0/23 2/22 3/15 4/19 4/12 liv agm ejz 1.08gm Z P<.1 + 257.mg n.s.s. 0/65 0/20 6/23 1/21 2/14 (2/19 1/12) ehp agm ejz 12.3gm * P<.09 + 3.30gm n.s.s. 1/67 1/20 2/24 1/24 0/15 2/19 2/15 for epo ejz 5.19gm * P<.2 863.mg n.s.s. 0/51 1/9 1/19 0/6 0/7 1/3 0/1 ehp ang ejz 8.03gm Z P<.7 951.mg n.s.s. 0/56 1/13 2/19 2/8 4/11 0/8 0/2 liv hpt ejz 25.2gm * P<.5 4.11gm n.s.s. 0/62 0/18 0/23 0/17 1/13 0/12 0/9 tba mix ejz 26.1mg Z P<.0005 16.2mg 47.9mg 15/80 7/30 25/30 24/30 (18/29 23/30 21/26) 6501 R f cdr inh 26w78 1113m 0 3.19mg 15.9mg 63.8mg Hong;jtxe,7,909-924;1981/1980 liv hes ejs 115.mg * P<.03 28.1mg n.s.s. 0/8 0/8 0/8 2/8 liv nnd ejs no dre P=1. 43.4mg n.s.s. 0/8 0/8 1/8 0/8 6502 R f cdr inh 43w95 1113n 0 4.35mg 21.7mg 87.0mg liv hes ejs 69.5mg * P<.0005 + 34.4mg 195.mg 0/16 0/16 4/12 7/16 liv hpc ejs 225.mg * P<.02 77.6mg n.s.s. 0/16 0/16 1/12 3/16 liv nnd ejs 315.mg * P<.3 95.4mg n.s.s. 0/16 0/16 2/12 1/16 6503 R m cdr inh 26w78 1113m 0 2.23mg 11.2mg 44.6mg liv nnd ejs 11.5mg Z P<.02 3.43mg n.s.s. 0/8 0/8 3/8 (1/8) liv hpc ejs 52.9mg * P<.04 15.9mg n.s.s. 0/8 0/8 1/8 2/8 6504 R m cdr inh 43w95 1113n 0 3.04mg 15.2mg 60.9mg liv nnd ejs 34.6mg Z P<.008 11.9mg 598.mg 0/16 0/10 4/16 (0/16) liv hes ejs 103.mg * P<.002 + 41.7mg 483.mg 0/16 0/10 1/16 5/16 liv hpc ejs 265.mg * P<.1 69.5mg n.s.s. 1/16 0/10 0/16 3/16 6505 R f f34 inh 6m24 1536m 0 4.80mg Drew;txap,68,120-130;1983/Haseman pers.comm. liv nnd e 17.6mg P<.0005 8.77mg 63.2mg 4/112 15/75 mgl fba e 15.1mg P<.03 + 6.50mg n.s.s. 24/112 28/76 --- hes e 91.2mg P<.2 + 23.2mg n.s.s. 2/112 4/76 liv hpc e 103.mg P<.2 25.8mg n.s.s. 1/112 3/75 6506 R f f34 inh 12m24 1536n 0 9.60mg mgl fba e 14.6mg P<.0005 + 7.52mg 52.0mg 24/112 28/56 liv nnd e 16.2mg P<.0005 9.16mg 35.0mg 4/112 20/56 --- hes e 29.5mg P<.0005 + 14.5mg 85.5mg 2/112 12/56 mgl adc e 38.0mg P<.003 + 16.6mg 272.mg 5/112 11/56 liv hpc e 101.mg P<.03 + 31.8mg n.s.s. 1/112 4/56 6507 R f f34 inh 18m24 1536o 0 14.4mg mgl fba e 29.7mg P<.004 + 13.8mg 269.mg 24/112 24/55 --- hes e 32.8mg P<.0005 + 17.4mg 78.1mg 2/112 15/55 liv hpc e 65.2mg P<.0005 + 28.5mg 255.mg 1/112 8/54 mgl adc e 74.2mg P<.02 + 29.1mg n.s.s. 5/112 9/55 liv nnd e 96.3mg P<.03 34.1mg n.s.s. 4/112 7/54 6508 R f f34 inh 24m24 1536r 0 19.1mg --- hes e 23.6mg P<.0005 + 14.2mg 43.9mg 2/112 24/55 mgl fba e 32.9mg P<.002 + 16.3mg 153.mg 24/112 26/55 liv hpc e 77.2mg P<.0005 + 35.3mg 260.mg 1/112 9/55 liv nnd e 166.mg P<.08 52.2mg n.s.s. 4/112 6/55 mgl adc e 264.mg P<.3 + 62.1mg n.s.s. 5/112 5/55 6509 R f sda inh 71w71 BT4001 0 534.mg Maltoni;anya,534,145-159;1988/1984 bra neu egjv 184.mg P<.0005 + 118.mg 306.mg 0/60 32/53 liv ang egjv 240.mg P<.0005 + 150.mg 415.mg 0/60 27/53 zym car egjv 1.19gm P<.007 + 501.mg 18.9gm 1/60 8/54 liv hpc egjv 1.72gm P<.006 + 654.mg 17.3gm 0/60 5/53 liv agm egjv 9.13gm P<.3 1.49gm n.s.s. 0/60 1/54 tba mix egjv 70.5mg P<.0005 34.1mg 172.mg 35/60 52/54 6510 R f sda inh 12m30 1BT1 0 2.53mg 16.7mg 29.9mg 149.mg 419.mg 840.mg Maltoni;aric,2,1-533;1984/ 1977a/1981 liv hpt ejz 244.mg Z P<.003 + 92.4mg 1.30gm 0/28 0/27 0/21 5/26 (2/23 1/17 0/16) liv ang ejz 735.mg Z P<.0005 + 427.mg 2.16gm 0/29 1/29 2/26 6/28 7/24 10/25 (4/25) zym car ejz 3.64gm * P<.0005 + 1.87gm 10.5gm 0/29 0/30 0/30 1/30 1/30 4/30 6/30 bra neu ejz 4.85gm * P<.0005 + 2.19gm 15.9gm 0/29 0/30 0/27 0/27 2/25 1/27 5/26 liv agm ejz 3.14gm * P<.04 + 789.mg n.s.s. 0/26 0/24 1/15 0/17 0/14 2/7 0/2 ehp ang ejz 21.4gm * P<.4 4.75gm n.s.s. 0/29 0/30 1/30 1/30 1/30 2/30 1/30 ehp agm ejz 94.9gm * P<.9 5.40gm n.s.s. 2/29 2/30 0/29 0/30 1/28 2/30 1/29 kid nep ejz no dre P=1. 4.75gm n.s.s. 0/29 1/29 4/27 4/28 1/25 1/26 2/25 tba mix ejz 2.77gm * P<.3 778.mg n.s.s. 19/29 16/30 15/30 20/30 18/30 22/30 20/30 6511 R f sda gav 12m30 1BT11 0 .905mg 4.38mg 13.2mg liv ang ejz 38.6mg * P<.0005 + 21.2mg 84.3mg 0/39 0/37 6/34 9/35 kid nep ejz 182.mg * P<.1 + 44.8mg n.s.s. 0/24 0/31 1/23 1/18 liv agm ejz 207.mg * P<.03 + 51.0mg n.s.s. 0/27 0/32 0/26 2/21 ehp agm ejz 408.mg * P<.5 50.4mg n.s.s. 0/25 1/31 0/25 1/18 ehp ang ejz 454.mg * P<.4 73.0mg n.s.s. 0/39 2/38 0/39 2/36 liv hpt ejz no dre P=1. 8.72mg n.s.s. 0/40 0/40 0/40 0/40 zym car ejz no dre P=1. 124.mg n.s.s. 1/36 0/36 1/37 0/29 tba mix ejz 35.2mg * P<.07 13.2mg n.s.s. 17/40 19/40 18/40 25/40 6512 R f sda inh 12m30 1BT15 0 50.6ug .270mg .577mg 1.44mg mgl adc ejz 1.66mg Z P<.0005 + .895mg 6.68mg 6/60 12/60 22/60 21/60 (15/60) liv ang ejz 21.0mg * P<.002 + 7.96mg 106.mg 0/44 0/55 0/47 1/46 4/40 liv agm ejz 60.1mg * P<.1 9.78mg n.s.s. 0/34 0/35 0/32 0/29 1/20 zym car ejz 44.6mg * P<.2 13.5mg n.s.s. 0/52 0/53 1/57 1/54 1/52 ehp agm ejz 75.1mg * P<.5 12.2mg n.s.s. 0/35 0/39 0/34 1/36 0/26 liv hpt ejz no dre P=1. .758mg n.s.s. 0/60 0/60 0/60 0/60 0/60 tba mix ejz 1.09mg * P<.004 .503mg 10.5mg 43/60 46/60 59/60 54/60 55/60 6513 R f sda inh 12m32 1BT2 0 4.77mg 7.37mg 12.0mg liv ang ejz 113.mg * P<.002 + 56.9mg 369.mg 0/68 1/43 5/46 5/44 mgl adc ejz 141.mg * P<.007 + 69.1mg 2.20gm 1/100 3/60 6/60 5/60 liv hpt ejz 140.mg * P<.05 + 34.4mg n.s.s. 0/19 0/16 0/11 2/7 kid nep ejz 230.mg * P<.03 + 99.3mg n.s.s. 0/86 2/55 3/54 2/57 liv agm ejz 378.mg * P<.07 + 92.9mg n.s.s. 0/44 0/27 0/29 2/24 ehp agm ejz 399.mg * P<.2 98.1mg n.s.s. 0/51 0/29 1/32 1/24 zym car ejz 1.07gm * P<.7 144.mg n.s.s. 2/95 1/59 4/57 1/59 tba mix ejz 37.4mg * P<.009 18.6mg 1.25gm 34/100 27/60 33/60 31/60 6514 R f sda gav 14m30 1BT27 0 8.82ug 97.3ug .294mg liv ang ejz 3.58mg * P<.07 + 1.08mg n.s.s. 0/23 0/18 1/19 2/29 zym car ejz 5.05mg * P<.2 1.30mg n.s.s. 1/28 0/25 0/25 3/32 ehp ang ejz 10.9mg * P<.2 1.78mg n.s.s. 0/25 0/18 0/19 1/29 liv agm ejz no dre P=1. .303mg n.s.s. 0/5 0/5 1/3 0/5 liv hpt ejz no dre P=1. .187mg n.s.s. 0/75 0/75 0/75 0/75 tba mix ejz .878mg * P<.05 .358mg n.s.s. 39/75 46/75 35/73 53/75 6515 R f sda inh 12m26 1BT9 0 2.99mg mgl adc ejz 5.91mg P<.0005 + 3.83mg 13.7mg 5/50 59/150 liv ang ejz 20.2mg P<.007 + 10.4mg 213.mg 0/38 12/110 liv agm ejz 30.7mg P<.04 + 12.5mg n.s.s. 0/37 6/82 ehp ang ejz 52.9mg P<.08 + 21.6mg n.s.s. 0/41 6/139 zym car ejz 67.9mg P<.09 + 25.8mg n.s.s. 0/49 5/148 kid nep ejz 17.5mg P<.3 2.83mg n.s.s. 0/8 1/8 ehp agm ejz 115.mg P<.2 34.9mg n.s.s. 0/50 3/150 liv hpt ejz no dre P=1. 105.mg n.s.s. 0/50 0/150 tba mix ejz 2.12mg P<.0005 1.30mg 5.66mg 29/50 129/150 6516 R f sda inh 6m30 1BT10m () 0 31.1mg 50.2mg zym car ejyz 1.20gm * P<.008 + 415.mg 20.2gm 0/119 0/59 4/59 liv agm ejyz 913.mg * P<.1 149.mg n.s.s. 0/51 0/15 1/9 liv ang ejyz 4.46gm * P<.4 726.mg n.s.s. 0/114 1/52 0/55 liv hpt ejyz no dre P=1. 354.mg n.s.s. 0/120 0/60 0/60 tba mix ejyz 309.mg * P<.5 63.2mg n.s.s. 84/120 40/59 46/60 6517 R f sda inh 6m31 1BT10n () 0 28.3mg 50.2mg mgl adc ejyz 291.mg * P<.006 + 140.mg 4.08gm 13/120 12/60 16/59 zym car ejyz 569.mg * P<.0005 + 268.mg 1.67gm 0/119 3/59 6/59 liv hpt ejyz 357.mg * P<.1 + 87.8mg n.s.s. 0/26 2/14 0/5 liv agm ejyz 507.mg * P<.02 + 153.mg n.s.s. 0/51 1/24 2/14 ehp ang ejyz 2.42gm * P<.4 395.mg n.s.s. 0/62 1/32 0/24 liv ang ejyz 2.46gm * P<.2 604.mg n.s.s. 0/114 1/54 1/55 ehp agm ejyz 2.99gm * P<.2 486.mg n.s.s. 0/78 0/39 1/30 kid nep ejyz 3.14gm * P<.2 511.mg n.s.s. 0/80 0/40 1/32 bra neu ejyz 3.63gm * P<.2 592.mg n.s.s. 0/89 0/41 1/40 tba mix ejyz 51.5mg * P<.002 26.8mg 224.mg 84/120 51/60 53/59 6518 R m sda inh 12m30 1BT1 0 1.77mg 10.1mg 19.5mg 113.mg 306.mg 737.mg liv ang ejz 875.mg Z P<.0005 + 426.mg 3.28gm 0/22 0/26 1/28 0/22 6/26 3/17 (3/21) zym car ejz 2.32gm * P<.0005 + 1.18gm 6.25gm 0/28 0/29 0/29 3/29 1/29 3/29 10/30 bra neu ejz 4.58gm * P<.006 + 1.87gm 66.3gm 0/22 0/26 0/28 0/22 2/27 2/21 2/22 kid nep ejz 2.96gm * P<.02 + 1.28gm n.s.s. 0/22 0/26 1/28 2/22 5/26 4/18 3/21 ehp agm ejz 8.18gm * P<.05 + 2.60gm n.s.s. 0/28 0/29 0/29 1/27 1/27 2/29 2/29 liv hpt ejz 13.4gm * P<.2 1.95gm n.s.s. 0/19 0/22 1/25 0/20 0/24 0/10 1/8 ehp ang ejz 14.9gm * P<.3 3.33gm n.s.s. 0/29 1/30 1/29 0/30 2/30 1/29 2/30 tba mix ejz 950.mg * P<.0005 499.mg 3.06gm 6/29 8/30 11/29 10/30 15/30 13/29 21/30 6519 R m sda gav 12m30 1BT11 0 .968mg 4.38mg 15.1mg liv ang ejz 57.4mg * P<.0005 + 29.5mg 147.mg 0/37 0/34 4/39 8/36 kid nep ejz 102.mg * P<.2 30.9mg n.s.s. 0/24 0/17 2/16 1/15 zym car ejz 315.mg * P<.2 77.4mg n.s.s. 0/33 0/28 1/30 1/31 ehp agm ejz 409.mg * P<.2 66.6mg n.s.s. 0/24 0/18 0/17 1/21 liv agm ejz 430.mg * P<.2 70.0mg n.s.s. 0/27 0/19 0/18 1/22 liv hpt ejz no dre P=1. 9.26mg n.s.s. 0/40 0/40 0/40 0/40 tba mix ejz 37.9mg * P<.0005 19.2mg 160.mg 7/40 3/40 9/40 17/40 6520 R m sda inh 12m32 1BT15 0 33.4ug .167mg .354mg .944mg ehp ang ejz 11.7mg * P<.4 2.87mg n.s.s. 0/13 0/11 0/20 2/15 0/11 ehp agm ejz 18.0mg * P<.2 5.51mg n.s.s. 1/21 0/31 0/38 2/38 3/38 kid nep ejz 28.9mg * P<.2 4.71mg n.s.s. 0/13 0/12 0/21 0/17 1/15 zym car ejz 50.4mg * P<.4 9.30mg n.s.s. 2/35 1/51 0/50 1/46 3/54 liv ang ejz 75.8mg * P<.2 12.3mg n.s.s. 0/25 0/48 0/43 0/42 1/41 liv hpt ejz no dre P=1. .555mg n.s.s. 0/60 0/60 0/60 0/60 0/60 tba mix ejz 8.67mg * P<.3 2.39mg n.s.s. 17/60 18/60 22/60 21/60 23/60 6521 R m sda inh 12m29 1BT2 0 3.77mg 5.66mg 7.80mg kid nep ejz 37.8mg * P<.002 + 22.6mg 108.mg 0/69 8/47 8/51 5/54 liv ang ejz 76.7mg * P<.002 + 34.8mg 275.mg 0/61 0/37 1/36 7/42 liv agm ejz 106.mg * P<.08 + 32.0mg n.s.s. 0/34 1/24 0/18 2/19 zym car ejz 315.mg * P<.05 + 95.4mg n.s.s. 0/82 0/57 0/57 3/59 liv hpt ejz 152.mg * P<.3 24.8mg n.s.s. 0/16 0/12 0/7 1/10 ehp ang ejz no dre P=1. 201.mg n.s.s. 2/85 0/60 0/59 1/60 tba mix ejz 66.2mg * P<.4 18.4mg n.s.s. 26/85 19/60 23/59 22/60 6522 R m sda gav 14m30 1BT27 0 8.82ug 97.3ug .313mg zym car ejz 4.75mg * P<.06 + 1.17mg n.s.s. 0/13 0/20 0/20 2/23 liv hpt ejz 3.36mg * P<.3 .827mg n.s.s. 0/11 0/13 1/15 1/16 liv ang ejz 8.45mg * P<.2 1.38mg n.s.s. 0/11 0/15 0/15 1/21 tba mix ejz 16.1mg * P<.8 1.39mg n.s.s. 13/75 15/75 17/75 15/74 6523 R m sda inh 12m29 1BT9 0 1.89mg ehp agm ejz 31.4mg P<.03 + 14.2mg n.s.s. 0/48 8/143 liv agm ejz 54.3mg P<.3 13.3mg n.s.s. 0/23 2/61 liv ang ejz 62.4mg P<.3 15.4mg n.s.s. 0/29 2/70 ehp ang ejz 63.0mg P<.2 19.1mg n.s.s. 0/34 3/106 zym car ejz 63.3mg P<.2 21.9mg n.s.s. 0/49 4/142 liv hpt ejz no dre P=1. 81.6mg n.s.s. 0/50 0/150 tba mix ejz 8.44mg P<.05 3.99mg n.s.s. 10/48 52/144 6524 R m sda inh 6m27 1BT10m () 0 24.1mg 38.8mg zym car ejyz 284.mg * P<.0005 + 138.mg 832.mg 0/105 5/57 5/56 ehp ang ejyz 468.mg * P<.2 115.mg n.s.s. 0/37 2/20 0/17 liv agm ejyz 580.mg * P<.2 94.3mg n.s.s. 0/25 0/15 1/9 liv ang ejyz 871.mg * P<.2 264.mg n.s.s. 0/61 2/49 1/51 ehp agm ejyz 5.81gm * P<.9 225.mg n.s.s. 1/39 0/27 1/22 liv hpt ejyz no dre P=1. 225.mg n.s.s. 0/120 0/60 0/60 tba mix ejyz 134.mg * P<.03 59.7mg n.s.s. 25/107 23/59 22/59 6525 R m sda inh 6m32 1BT10n () 0 19.8mg 32.1mg zym car ejyz 226.mg \ P<.0005 + 92.4mg 846.mg 0/105 6/59 (2/57) liv agm ejyz 1.03gm * P<.5 168.mg n.s.s. 0/25 1/17 0/16 kid nep ejyz 1.94gm * P<.6 317.mg n.s.s. 0/39 1/32 0/30 liv hpt ejyz no dre P=1. 271.mg n.s.s. 0/109 0/60 0/60 ehp agm ejyz no dre P=1. 136.mg n.s.s. 1/39 0/31 0/29 tba mix ejyz 284.mg * P<.2 94.1mg n.s.s. 25/107 22/60 18/60 6526 R m sda inh 12m30 1440 0 21.4mg Radike;enhp,41,59-62;1981 liv hpc e 40.8mg P<.0005 + 26.7mg 67.3mg 1/80 35/80 liv ang e 90.0mg P<.0005 + 51.7mg 177.mg 0/80 18/80 adr tum e 251.mg P<.003 108.mg 1.09gm 0/80 7/80 liv mix e 294.mg P<.004 + 120.mg 1.93gm 0/80 6/80 pit tum e 138.mg P<.02 61.0mg n.s.s. 8/80 19/80 tba mix e 17.3mg P<.0005 + 11.6mg 28.1mg 16/80 63/80 6527 R f wis inh 52w52 1170 0 1.12gm Feron;txcy,13,131-141;1979/1979a liv ang ek 209.mg P<.002 + 80.8mg 884.mg 0/10 6/10 nas oec ek 276.mg P<.004 + 101.mg 1.93gm 0/10 5/10 zym sqc ek 857.mg P<.09 + 209.mg n.s.s. 0/10 2/10 liv hpc ek 1.81gm P<.3 + 295.mg n.s.s. 0/10 1/10 liv nnd ek 1.81gm P<.3 + 295.mg n.s.s. 0/10 1/10 lun ppa ek 1.81gm P<.3 295.mg n.s.s. 0/10 1/10 6528 R m wis inh 12m30 1BT17 0 36.6ug Maltoni;aric,2,1-533;1984/1977a/1981 ehp agm ejz .370mg P<.01 + .140mg 15.6mg 0/49 5/52 ehp ang ejz 1.05mg P<.05 + .318mg n.s.s. 0/84 3/86 liv agm ejz .654mg P<.3 .106mg n.s.s. 0/13 1/18 liv hpt ejz .728mg P<.3 .119mg n.s.s. 0/16 1/20 zym car ejz no dre P=1. .596mg n.s.s. 3/90 2/96 6529 R m wis inh 12m29 1BT7 0 2.05mg 10.6mg 18.6mg 120.mg 276.mg 479.mg liv ang ejz 518.mg * P<.0005 + 271.mg 1.32gm 0/34 0/22 1/17 3/18 3/11 3/14 8/12 zym car ejz 3.54gm * P<.002 + 1.22gm 21.2gm 0/36 0/22 0/18 0/19 0/12 2/16 2/18 bra neu ejz 4.14gm * P<.002 + 1.57gm 21.8gm 0/38 0/28 0/25 0/26 1/22 1/25 3/24 liv agm ejz 3.62gm * P<.1 + 860.mg n.s.s. 0/33 0/22 0/16 1/15 0/9 2/12 0/8 liv hpt ejz 4.86gm * P<.05 + 1.47gm n.s.s. 0/36 0/22 0/18 0/19 1/12 2/16 0/18 kid nep ejz 4.51gm * P<.2 1.04gm n.s.s. 0/34 1/22 0/17 2/17 0/11 2/14 1/12 ehp ang ejz 8.49gm * P<.6 991.mg n.s.s. 1/33 0/21 1/14 0/14 1/8 1/11 0/7 ehp agm ejz 72.7gm * P<.9 4.03gm n.s.s. 0/38 0/28 1/27 0/28 0/25 1/26 0/27 tba mix ejz 1.13gm * P<.02 485.mg n.s.s. 11/38 7/28 5/27 12/28 11/25 11/26 14/27 6530 R m wis inh 52w52 1170 0 781.mg Feron;txcy,13,131-141;1979/1979a liv ang ek 330.mg P<.03 + 98.3mg n.s.s. 0/10 3/9 zym sqc ek 330.mg P<.03 + 98.3mg n.s.s. 0/10 3/9 nas oec ek 533.mg P<.08 + 130.mg n.s.s. 0/10 2/9 liv hpc ek 1.14gm P<.3 + 185.mg n.s.s. 0/10 1/9 lun ppa ek no dre P=1. 362.mg n.s.s. 0/10 0/9 6531 R m wis inh 52w78 1760 0 1.07mg 10.7mg 321.mg Bi;eaes,10,281-289;1985/pers.comm. liv ang e 10.2mg Z P<.0005 + 4.36mg 32.7mg 0/19 0/20 7/19 (17/20) lun ang e 193.mg * P<.0005 + 88.3mg 617.mg 0/19 0/20 2/19 9/20 lun tum e 867.mg * P<.2 + 208.mg n.s.s. 1/19 1/20 3/19 4/20 bra tum e 5.82gm * P<.8 + 503.mg n.s.s. 0/19 0/20 2/19 1/20 ski tum e 5.82gm * P<.8 + 503.mg n.s.s. 0/19 0/20 2/19 1/20 nse tum e no dre P=1. + 469.mg n.s.s. 1/19 1/20 2/19 1/20 tes tum e no dre P=1. + 674.mg n.s.s. 0/19 0/20 1/19 0/20 tba mix e 5.44mg Z P<.0005 + 2.63mg 15.7mg 1/19 1/20 11/19 (19/20)

Mutagenicity in Salmonella: positive
SMILES Code for Vinyl chloride: C=CCl
InChI Code for Vinyl chloride: InChI=1/C2H3Cl/c1-2-3/h2H,1H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Vinyl chloride: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10